What is frova?

See the DrugPatentWatch profile for frova

What Is Frova and Why Is It Used?

Frova, whose generic name is fospropofol, is a sedative-hypnotic drug used for inducing sedation, especially in the preoperative setting, and in some medical procedures requiring deep sedation [1]. It was developed by Mallinckrodt Pharmaceuticals and approved by the U.S. Food and Drug Administration (FDA) in 2002.

How Does Frova Work?

Frova works by mimicking the effects of the neurotransmitter gamma-aminobutyric acid (GABA), which is responsible for inhibiting nerve activity and promoting relaxation. By augmenting GABA's action, Frova helps reduce anxiety and sedate patients, making it easier for them to undergo medical procedures [2].

Why Are Companies Challenging This Patent?

Fosalbin, marketed as Frova, has a patent that expires in 2024. Companies might be challenging this patent because they want to market generic versions of the drug once the patent expires, which will likely reduce their costs and increase market share [3].

What Side Effects Are Patients Asking About?

As with any medication, patients taking Frova may be concerned about side effects such as headache, dizziness, nausea, or fatigue. However, more severe effects like respiratory depression, hypotension, or allergic reactions are relatively rare but potentially life-threatening [4].

Can Biosimilars Enter Before Patent Expiration?

It is possible for biosimilars to enter the market before the patent expires, but this requires a complex process. Biosimilars have already entered the U.S. market for some other medications, but the approval process for biosimilars is often more challenging than for generic versions of small molecule drugs [5].

SOURCES:

[1] DrugPatentWatch.com: Fospropofol
[2] MedlinePlus Medical Encyclopedia: Fospropofol
[3] Patent Expiration Date for Fospropofol
[4] MedWatch Safety Alerts for Human Medical Products: Fospropofol (Frova)
[5] [Biosimilars in the US: A Guide for Healthcare Professionals](https://www.aacr.org/ Publications/Biosimilars-in-the-US-A-Guide-for-Healthcare-Professionals)